X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
JW-700 is a topical treatment designed to improve minoxidil efficacy which increases the enzymes needed for minoxidil to work, sulfotransferase enzymes, by up to 7x over a two-week period, for the treament of hair loss.
Lead Product(s): Minoxidil
Therapeutic Area: Dermatology Product Name: JW-700
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
This study aims to investigate if the dopamine receptor antagonist Pimozide can be used effectively treat COVID-19 for tinnitus, emergent symptoms lasting longer than 4 weeks since onset.
Lead Product(s): Pimozide
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: JW-600
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Applied Biology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
Induction of the sulfotransferase enzyme in hair follicles increases the sulfonation capacity of minoxidil; thus, increasing the response level to oral and topical minoxidil in the treatment of alopecia.
Lead Product(s): Minoxidil
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
The product has been named JW-500 to be added to a line of other clinical stage products currently under development at the Company. Jupiter Wellness plans to file for a pre-IND meeting with the US FDA within the next 12 months and intends to seek Orphan Drug Designation.
Lead Product(s): JW-500
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: JW-500
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rejoy Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 20, 2022
Details:
JW-100 (cannabidiol), met its primary endpoint in a recently completed Phase 1-equivalent international study in which Jupiter’s topical formulation cleared or reduced eczema following two weeks of use.
Lead Product(s): Cannabidiol,Aspartame
Therapeutic Area: Dermatology Product Name: JW-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2021
Details:
Jupiter Wellness previously reported that in a double-blinded, placebo controlled clinical trial of 55 patients using JW-100 was shown to significantly reduce ISGA scores in 50% of adult patients suffering from eczema after two weeks of use.
Lead Product(s): Cannabidiol,Aspartame
Therapeutic Area: Dermatology Product Name: JW-100
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2021
Details:
Jupiter Wellness commenced patient enrollment for skin cancer. Jupiter's JW-200 is designed to provide action and relief in the treatment of eczema, Actinic Keratosis, the most common precancer that forms on skin as a result of exposure to ultraviolet (UV) rays.
Lead Product(s): Cannabidiol,Aspartame
Therapeutic Area: Dermatology Product Name: JW-100
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
